MeiraGTx Reacquires XLRP Therapy from J&J for $25M Upfront
Event summary
- MeiraGTx acquires botaretigene sparoparvovec (bota-vec) from J&J for $25M upfront plus milestones and royalties.
- Phase 3 LUMEOS trial data shows clinically meaningful improvements in XLRP patients despite primary endpoint miss.
- MeiraGTx plans global regulatory filings with potential U.S. and EU approvals targeted for 2027.
- Company aims to become commercial-stage with two product launches within two years.
The big picture
MeiraGTx's reacquisition of bota-vec positions it to address a severe unmet need in X-linked retinitis pigmentosa, a rare inherited retinal disease with no current treatments. The deal reflects growing industry focus on gene therapies for orphan diseases, where regulatory incentives and concentrated patient populations can accelerate approvals and commercialization. With $25M upfront and potential milestone payments, the transaction underscores the strategic value of late-stage assets in the genetic medicines space.
What we're watching
- Regulatory Pathway
- Whether the compelling secondary endpoints will be sufficient for approval despite the primary endpoint miss.
- Commercial Execution
- The pace at which MeiraGTx can transition from clinical-stage to commercial operations with two products.
- Market Opportunity
- How the concentrated IRD patient population will impact adoption and revenue potential for bota-vec.
Related topics